NeoGenomics, Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; comparisons are with FY 2011. This is an annual filing, and the supplied filing text does not provide a clear standalone fourth-quarter income statement.
Business context
NeoGenomics operates U.S. cancer-focused clinical laboratories providing cytogenetics, FISH, flow cytometry, immunohistochemistry and molecular testing. It serves hospitals, pathology practices, oncologists and other clinicians through technical-only and full-service testing. The company reported one operating segment.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $59.867 million | $43.484 million |
| Gross profit / margin | $26.836 million / 44.8% | $19.428 million / 44.7% |
| Operating income (loss) | $1.211 million | ($0.409 million) |
| Net income (loss) | $65,000 | ($1.177 million) |
| Adjusted EBITDA (non-GAAP) | $5.998 million | $2.134 million |
| Operating cash flow | ($492,000) | $69,000 |
- Cases increased 49.8% to 73,773 and tests performed increased 50.2% to 114,606. Average revenue per test fell 8.4% to $522; average revenue per requisition fell 8.1% to $812.
- Cost of revenue was $33.031 million, or 55.2% of revenue. Cost per test declined 8.6% to $288.21, which management attributed to productivity improvements, lower send-outs and changes in test mix.
- Operating expenses totaled $25.625 million: general and administrative $15.843 million, R&D $2.281 million and sales and marketing $7.501 million. R&D rose substantially as the company expanded test development.
- Cash and cash equivalents were $1.868 million at year-end; working capital was $823,000. Net accounts receivable rose to $14.034 million from $7.894 million, while the doubtful-account allowance was $3.002 million.
- Year-end revolving credit borrowings were $8.458 million; equipment capital lease obligations totaled $5.309 million. Investing cash use was $3.652 million and financing cash provided was $3.384 million.
Material changes and unusual items
- Revenue growth reflected new clients, including one with more than 30 locations, and increased penetration of existing clients. A large oncology practice represented 14.9% of revenue, up from 11.3% in 2011.
- Expiration of Medicare’s Technical Component Grandfather clause on June 30, 2012 required direct billing of certain hospital clients. Management reported approximately $2.6 million less revenue in the second half of 2012 versus the comparable 2011 period and described lower reimbursement and slower collections.
- Management attributed increased receivables and operating cash use to growth, billing-code adoption issues for molecular tests, the Medicare billing change and Blue Cross Blue Shield administrative changes.
- In January 2012, the company acquired a license to Health Discovery Corporation technology for approximately $3.0 million, paid with $1.0 million cash and 1.36 million shares valued at $1.945 million. Related intangible assets had a year-end net book value of $2.8 million.
- The company reported net income of only $65,000 despite positive operating income, with net interest and other expense of $1.146 million. No income tax provision was recorded; net operating loss carryforwards were used, and deferred tax assets remained fully reserved.
Outlook, risks and contingencies
- Management expected new assays, including a Barrett’s Esophagus test, and continued molecular test development to support growth in 2013. It anticipated modestly higher sales and marketing expense, substantial R&D investment and approximately $5–6 million of capital equipment purchases. These are management expectations, not formal revenue or earnings guidance.
- A January 2013 credit amendment increased the facility cap to $10 million from $9 million; the company said it had approximately $1.1 million of availability after the amendment. The facility includes financial covenants and is secured by company assets, including accounts receivable. Management believed resources were adequate, while warning that further capital might be needed and could be unavailable on favorable terms.
- Key risks include reimbursement reductions or coverage limits, payer collection delays, proposed FDA oversight of laboratory-developed tests, complex healthcare compliance requirements, competition and customer internalization of testing, and dependence on a major client.
- Supply and operating risks include reliance on a dominant FISH-probe supplier and a primary specimen-shipping carrier, capacity and staffing needs, and lack of backup generators at the Irvine and Nashville laboratories. Seasonal volume declines and weather disruptions may also affect results.
- The filing reports no current legal proceedings believed material. The independent auditor gave an unqualified opinion on the financial statements; the auditor did not attest to internal control, while management concluded controls were effective.
Important facts for investors to verify
- Whether receivables convert to cash as expected, especially older balances, and whether operating cash flow improves after the billing changes.
- Actual reimbursement and margin effects of the Technical Component Grandfather clause expiration and payer policies.
- Availability under the amended credit facility, covenant compliance, debt and lease repayment needs, and funding for planned capital spending.
- Whether new tests and licensed technology generate commercial revenue sufficient to support R&D and potential license milestones or royalties.
- Customer concentration, share dilution from equity awards and financing, and progress on capacity, staffing and backup infrastructure.